Hyundai Heavy set to dive into biotech industry Hyundai Heavy Industries Group establishes AMCBIO to develop new drugs
Translated by Kim So-in 공개 2022-02-09 08:11:51
이 기사는 2022년 02월 09일 08:07 thebell 에 표출된 기사입니다.
South Korea’s Hyundai Heavy Industries Group has established AMCBIO in a bid to make a foray into the biotech industry amid its ongoing efforts to secure a new growth engine since its listing last year.According to the Fair Trade Commission (FTC), AMCBIO has been newly incorporated into Hyundai Heavy Industries Group in December 2021. The business purpose of AMCBIO encompasses various areas of new drug development, including research and business development advisory services.
Experts expect that the group will enter the new drug development business with the establishment of AMCBIO. It has reportedly contacted several domestic biotech firms since Hyundai Heavy Industries went public in September 2021.
“From the preparation stage for the listing, Hyundai Heavy Industries has been continuously considering entering the new drug development business to discover new growth engines,” said an industry source.
Separately, Hyundai Heavy Industries Holdings, the holding company of Hyundai Heavy Industries Group, Asan Medical Center, and Kakao, the operator of South Korea’s top mobile messenger app KakaoTalk, joined hands to enter the digital healthcare market. They established a joint venture called Asan Kakao Medical Data in 2019 to develop a big data platform, and acquired Mediplus Solution, a healthcare service company, in August 2021.
“It has been over three years since Asan Kakao Medical Data was established, but it hasn’t shown any remarkable results,” said an industry source. “Kakao launched Kakao Healthcare CIC (company-in-company) last year to enter the digital healthcare market, so it remains to be seen how it will create synergies with Asan Medical Center.”
Kakao established its in-house online healthcare platform in December 2021 to offer lifecycle-based smart healthcare services. Hwang Hee, a former professor at Seoul National University Bundang Hospital, was appointed to lead Kakao Healthcare CIC.
Hyundai Future Partners, the investment arm of Hyundai Heavy Industries Holdings, is likely to lead the group’s biotech business. The holding company established the investment firm in 2019 by injecting capital of 5 billion won ($4.17 million). In November 2021, the holding company formed a 34 billion won fund in partnership with Mirae Asset Capital.
Hyundai Future Partners is expected to play a significant role in discovering future growth engines of Hyundai Heavy Industries. (Reporting by Sook Hong)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- 우리금융 "롯데손보 M&A, 과도한 가격 부담 안한다"
- 신한캐피탈, 지속성장 포트폴리오 리밸런싱 체계 강화
- 하나금융, ELS 악재에도 실적 선방…확고한 수익 기반
- 하나금융, 자본비율 하락에도 주주환원 강화 의지
- 국민연금, '역대 최대 1.5조' 출자사업 닻 올렸다
- [도전 직면한 하이브 멀티레이블]하이브, 강한 자율성 보장 '양날의 검' 됐나
- [퍼포먼스&스톡]꺾여버린 기세에…포스코홀딩스, '자사주 소각' 카드 재소환
- [퍼포먼스&스톡]LG엔솔 예견된 실적·주가 하락, 비용 절감 '집중'
- [퍼포먼스&스톡]포스코인터, 컨센서스 웃돌았지만 주가는 '주춤'
- 신한금융, ‘리딩금융’ 재탈환에 주주환원 강화 자신감